1. Home
  2. AZTR vs RDHL Comparison

AZTR vs RDHL Comparison

Compare AZTR & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.18

Market Cap

3.5M

Sector

Health Care

ML Signal

HOLD

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

N/A

Current Price

$0.85

Market Cap

4.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AZTR
RDHL
Founded
2014
2009
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5M
4.0M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
AZTR
RDHL
Price
$0.18
$0.85
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
1.3M
2.1M
Earning Date
05-08-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$381.91
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.57
52 Week High
$1.09
$2.79

Technical Indicators

Market Signals
Indicator
AZTR
RDHL
Relative Strength Index (RSI) 63.18 68.84
Support Level $0.15 $0.76
Resistance Level $0.23 $0.91
Average True Range (ATR) 0.01 0.09
MACD 0.01 0.04
Stochastic Oscillator 76.75 28.43

Price Performance

Historical Comparison
AZTR
RDHL

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About RDHL Redhill Biopharma Ltd.

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Share on Social Networks: